What's next for psychedelics after MDMA rejection?
Science (New York, N.Y.) – August 16, 2024
Source: PubMed
Summary
Despite a recent setback in MDMA therapy approval, the psychedelic medicine field continues advancing. Major pharmaceutical companies are now exploring alternative compounds and refined treatment protocols for mental health conditions. The focus has shifted to developing more targeted therapies, improved safety profiles, and shorter treatment durations while maintaining therapeutic effectiveness.
Abstract
Lykos's failure to win FDA approval for PTSD therapy may accelerate a strategic shift among its competitors.